The aim of this study was to characterize the clinical features of familial lupus, and determine its influence on damage accrual and survival using data from LUMINA, a longitudinal multiethnic US cohort. Familial lupus was defined as patients with a first-degree relative with systemic lupus erythematosus. Relative risks were estimated by logistic regression; odds ratios (ORs) and their 95% confidence intervals (CIs) were the measure of association for familial lupus. Hazard ratios were calculated using Cox proportional hazards adjusted for potential confounders for damage and survival. Of 644 patients, 32 had familial and 612 had sporadic lupus; both groups were of comparable age ($36 years). Patients with familial lupus were, in decreasing order of frequency, siblings, parents and children. In multivariable analyses, mucosal ulcers (OR ¼ 1.92, 95% CI 0.65-5.70), mitral valve prolapse (OR ¼ 1.74, 95% CI 0.50-6.10), cerebrovascular disease (OR ¼ 4.18, 95% CI 0.98-17.76) and oral contraceptive use (ever/never; OR ¼ 2.51, 95% CI 0.88-7.19) were more likely in familial lupus, but a history of low platelet count (<150,000/mm 3 ; OR ¼ 0.31, 95% CI 0.08-1.17) and pulmonary disease activity (OR ¼ 0.39, 95% CI 0.14-1.20) were less likely. However, none of these associations reached statistical significance. Familial lupus was not significantly associated with a shorter time to either damage accrual or death (HR ¼ 0.77, 95% CI 0.37-1.59, p ¼ 0.4746 and HR ¼ 0.20, 95% CI 0.03-1.47, p ¼ 0.2020, respectively). We conclude that although some clinical differences were observed between patients with familial and sporadic lupus, familial lupus was not associated with a significantly greater disease burden (damage, survival) than sporadic lupus. Lupus (2010) 19, 1331-1336.
Introduction
Although the etiology of systemic lupus erythematosus (SLE) remains elusive, environmental and genetic factors are known to influence its onset and clinical course. 1 As with other autoimmune diseases, the genetic basis of SLE is complex, with contribution from the major histocompatibility complex (MHC) genes and a multiplicity of other genes. 2 Lupus occurs more often within families (10-12%). Concordance rates are higher for monozygotic twins (24-56%) than dizygotic twins (2-5%); furthermore, a high degree of concordance in disease expression has been shown in some studies. [3] [4] [5] [6] Despite the preponderance of lupus within families, studies conducted so far have failed to show distinctive immunological and clinical features between patients with sporadic and familial lupus, [7] [8] [9] including studies conducted in populations with a high degree of consanguinity. 8, 10 Nevertheless, we hypothesized that patients with familial lupus, who may have a higher genetic load than patients with sporadic lupus, may also have more severe disease manifestations which in turn may affect their damage accrual and their survival.
Methods
Population LUMINA (Lupus in Minorities, Nature versus Nurture) is a longitudinal cohort of patients with SLE. 11 All patients meet the ACR criteria for SLE classification, 12 have disease duration of 5 years, are !16 years of age, of defined ethnicity (African American, Hispanic (from Texas or Puerto Rico), or Caucasian), and live in the geographic recruitment areas of the participating centers (the University of Alabama at Birmingham, the University of Texas Heath Science Center at Houston, and the University of Puerto Rico Medical Sciences Campus). The Institutional Review Board of these centers approved the study; written informed consent was obtained according to the Declaration of Helsinki.
Every patient had a baseline or enrollment visit (T0); follow-up visits were conducted every 6 months during the first year (T0.5 and T1, respectively), and yearly thereafter. At each visit, the patients were interviewed and examined, and laboratory tests performed. Clinical data from missed study visits were obtained by review of all available medical records. Disease duration was defined as the time from the date the patients met four ACR criteria for SLE (TD) to T0. Duration of follow-up was the period between T0 and the last visit (TL).
Familial lupus, our primary end-point, was defined as patients with any first-degree relative (father, mother, siblings or children) with lupus. This diagnosis was self-reported during the patients' study visits and verified by reviewing all available medical records. Patients without a selfreported family history of lupus were defined as having sporadic lupus.
Clinical information
As previously reported, 13 the LUMINA database includes variables from the following domains: socioeconomic-demographic, clinical, immunological, genetic, behavioral and psychological. These variables are measured at all visits. Only the variables included in these analyses will be described.
Variables included from the socioeconomicdemographic domain were age, ethnicity, education, poverty, 14 health-related behaviors, marital status and health insurance. Variables from the behavioral and psychological domains were social support, 15 abnormal illness-related behaviors (IBQ), 16 and learned helplessness. 17 Clinical variables included were the number of ACR criteria at T0, onset type (acute versus insidious, if otherwise), follow-up time (T0-TL, as defined), disease manifestations, disease activity and damage, immunological variables and medications. Cumulative exposure to glucocorticoids, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, statins, nonsteroidal anti-inflammatory drugs, low-dose aspirin, oral contraceptives, hormonal replacement therapy, warfarin and angiotensin-converting enzyme inhibitors was also recorded.
Disease activity was assessed using the Systemic Lupus Activity Measure-Revised (SLAM-R) 18 at T0 and at every visit. For the purpose of this study, the average SLAM-R score for all visits (TD to TL) was calculated as a measure of disease activity over time. Damage at T0 and TL was assessed using the SLICC/ACR Damage Index (SDI). 19 
Laboratory assays
Autoantibodies were obtained at T0 included antinuclear antibodies (ANA, by immunofluorescence using HEp-2 cell line), anti-double-stranded DNA (anti-dsDNA, by immunofluorescence against Crithidia luciliae), anti-Smith, anti-RNP, anti-La and anti-Ro (by immunodiffusion) and antiphospholipid antibodies (aPL, by enzyme-liked immunosorbent assay and /or lupus anticoagulant by the Staclot assay). Selected HLA and FCGR3A specificities were also included. In addition, the following laboratory variables were recorded at T0: non-fasting serum lipoproteins, and serum C-reactive protein (CRP), measured as highsensitivity CRP (hs-CRP; high > 9 mg/l or the highest tertile for the distribution of our patients' values) by immunometric assay (Immulite 2000; Diagnostic Products, Los Angeles, CA, USA) using T0 patients' sera.
Statistical analyses
Features from the different domains were compared between those patients with familial and sporadic lupus using Student's t and Chi-square tests for continuous and categorical variables, respectively. Variables with p .10 were entered into multivariable logistic regression models to examine their independent association with familial lupus; relative risks were estimated using odds ratios (ORs) and their corresponding 95% confidence intervals (CIs). The role of familial lupus in the time-to-the development of damage and death (Hazard ratios (HRs)) was examined by Cox multivariable regressions, adjusting for variables previously found to be associated with damage accrual 
Results
The cohort consisted of 644 patients; 32 of them had familial lupus and 612 the sporadic form; the majority of patients in both groups were women ($90%) and their mean (standard deviation SD) age was comparable; 36.6 AE (12.5) years. All ethnic groups were represented, and although there were some differences in the distribution of these groups in the sporadic versus the familial form of the disease (Texan Hispanic: 19% vs.6%, Puerto Rican Hispanic: 16% vs.9%, African American: 37% vs.50% and Caucasian: 28% vs.34%), these differences were not statically significant ( Table 1 ). The mean SD of disease duration and follow-up times were also comparable: 1.7 (1.4) and 5.3 (4.0) years for familial, and 1.4 (1.4) and 4.6 (3.5) years for sporadic lupus. Of the first-degree relatives 50% (n ¼ 16) were siblings, 38% (n ¼ 12) parents and 12% (n ¼ 4) children.
Features associated with familial lupus
None of the socioeconomic-demographic variables examined were significantly associated with familial lupus. As shown in Table 1 , oral ulcers (60.3% vs. 78.1%, p ¼ .043) and cerebrovascular disease (3.8% vs. 12.5%, p ¼ .039) were significantly associated with familial lupus. None of the patients with familial lupus presented palpable purpura, subacute cutaneous lupus, livedo reticularis or pulmonary damage as determined by the SDI. As noted in Table 1 , there was a higher proportion of deceased patients (15.5%, n ¼ 97) among the sporadic and than among the familial form (3.1%, n ¼ 1), but the difference between these percentages was not significant. An increased in erythrocyte sedimentation rate was associated with sporadic lupus (76.8% vs. 56.3%, p ¼ .008). None of the autoantibodies, lipid profile and genetic variables (HLA and FCGR3A specificities) examined was found to be associated with familial lupus (data not shown except for the data for HLA-DRB1*1503, and HLA-DQB1*0602, which are noted in Table 1 ).
The exposure to hydroxychloroquine, cyclophosphamide and azathioprine was comparable in the two groups, but mycophenolate mofetil was more frequently used in the sporadic than in the familial form (10% vs. 0%). The use of glucocorticoids was comparable in both groups, but oral contraceptives were used more frequently in familial lupus than in the sporadic form (44% vs. 22 %, p ¼ .006). Other medications such as aspirin, statins, non-steroidal anti-inflammatories, hormonal replacement therapy, warfarin, and angiotensin-converting enzyme inhibitors were used comparably in both groups (data not shown).
Independent factors associated with familial lupus
As shown in Table 2 , in multivariable analyses, mucosal ulcers (OR ¼ 1.92, 95% CI 0.65-5.70), mitral valve prolapse (OR ¼ 1.74, 95% CI 0.50-6.10), cerebrovascular disease (OR ¼ 4.18, 95% CI 0.98-17.76) and oral contraceptive use (ever/never; OR ¼ 2.51, 95% CI 0.88-7.19) were more likely in familial lupus but statistical significance was not reached. The same was the case for the pulmonary domain of the SLAM-R and low platelet count (OR ¼ 0.39, 95% CI 0.14-1.20 and <150,000/mm 3 ; OR ¼ 0.31, 95% CI 0.08-1.17; respectively), that were less likely in familial lupus.
Longitudinal analysis of familial lupus
In the multivariable time-to-event analysis for damage accrual which included age, gender, ethnicity, highest dose of prednisone and number of ACR criteria, familial lupus was not significantly associated with either a shorter or a longer time-todamage accrual (HR ¼ 0.77, 95% CI 0.37-1.59, p ¼ .475) (data not shown).
Finally, in the multivariable time-to-event analysis for death which included age, gender, ethnicity, SDI baseline, SLAM-R baseline and poverty, familial lupus (HR 0.20, 95% CI 0.03-1.47, p ¼ .202) was not significantly associated with either a shorter or a longer time to death (data not shown).
Discussion
We have shown for the first time that familial lupus exerts no negative impact in terms of either a diminished survival or damage accrual. Furthermore, we did not find a distinct clinical or serological pattern distinguishing familial and sporadic lupus, despite the clear importance of genetic factors in the development of lupus. Even though none of the clinical manifestation reached significance, the possible association with cerebrovascular disease and oral contraceptive use is intriguing; however, no differences in the frequency of aPL antibodies or other thrombotic events were observed in patients with familial lupus. As in our study, an increased/decreased frequency of specific clinical and laboratory features such as photosensitivity, oral ulcers, malar rash, low platelet counts and/or anti-Ro antibodies have been reported in patients with familial lupus, but none of these findings have shown to be independently associated with the development of this form of lupus, 7-9 supporting the importance of environmental factors in the development of the phenotype. Furthermore, in the Chinese study of Wang et al., in which 136 patients with lupus nephritis were studied, including 34 with familial lupus, fever was the only manifestation independently associated with familial lupus, but the severity of lupus nephritis, as assessed histologically, was found to be similar in both patient groups. 20 The 5% prevalence of familial lupus observed in our study is similar to frequencies previously described, 8, 9 but lower than in studies of patients with a high degree of consanguinity. 10, 21 Several studies have shown that the genetic predisposition to the development of lupus, as well as its course, varies according with the ethnic/racial background of the patients studied. 13 Sestak et al., for example, in a study emanating from the US Lupus Family Registry and Repository, stratified their patients with familial and sporadic lupus by racial/ethnic group. 22 Although a similar clinical profile was found in patients with sporadic and familial lupus of the same racial/ethnic group, there were some differences between the groups; for example, there was an increased proportion of patients with arthritis and lupus erythematosus cell test positivity in patients with familial lupus of European ancestry, as compared with those of African and Hispanic ancestry. 22 The fact that no distinctive clinical, laboratory or genetic pattern emerged in familial lupus needs to be interpreted with caution; first, we only included first-degree relatives, which precluded comparing our study with others in which other relatives have also been included. Second, relatives of patients with lupus may present to a physician when relatively mild symptoms ensue, simply because they have a greater awareness of lupus; they may have less severe disease with an early diagnosis. Thus increased clinical awareness with a larger genetic load could result in the familial lupus phenotype appearing similar to sporadic lupus. Third, the sample size did not allow us to examine the ethnic groups separately; however, data from Sestak et al. suggest that there are no substantial differences between the racial/ethnic groups. 22 Fourth, we only examined MHC Class II and III genes and not others which have been associated with the disease or its different features. 2 Finally, our study did not include the full spectrum of the relatives' clinical features to assess the co-occurrence of SLE in these families and the possible presence of subphenotypes according to degree of familiarity (i.e. parents versus siblings).
In conclusion, familial lupus, as compared with sporadic lupus, is not associated with a significantly greater disease burden as evidenced by clinical manifestations, damage accrual and survival; thus patients with familial lupus should be treated similarly to patients with sporadic lupus, and worse outcomes are not to be expected among them.
